Shea Katherine Louise, Palanisamy Arvind
aClinical Fellow in Obstetric Anesthesia bAssistant Professor of Anaesthesia, Brigham and Women's Hospital Harvard Medical School, Boston, Massachusetts, USA.
Curr Opin Anaesthesiol. 2015 Jun;28(3):261-6. doi: 10.1097/ACO.0000000000000184.
Hypoxic-ischemic brain injury is a leading cause of mortality and morbidity in neonates. Treating such injury by interrupting the excitotoxic-oxidative cascade is of immense importance. This review will focus on novel techniques of neuroprotection and describe the latest advances in established therapeutic methods.
Although the primacy of therapeutic hypothermia in treating hypoxic-ischemic encephalopathy is well established, recent research establishes that the arbitrarily chosen regimen of cooling to 33°C for 72 h may indeed be the most appropriate method. The optimal duration of antenatal magnesium therapy for neuroprotection remains unsettled, though it is reassuring that even 12 h or less of magnesium therapy results in comparable neurological outcomes. Combining adjuvant therapies such as melatonin or erythropoietin with therapeutic hypothermia results in favorable neurological outcomes compared with hypothermia alone. Finally, stem cell-based therapies show considerable potential in preclinical studies.
Significant advances have occurred in the management of neonatal brain injury. With establishment of the optimal temperature and duration of hypothermia, combinatory therapies using adjuncts hold the greatest promise. Promising preclinical approaches such as stem cell-based therapy and use of noble gases need to be confirmed with clinical trials.
缺氧缺血性脑损伤是新生儿死亡和发病的主要原因。通过中断兴奋性毒性-氧化级联反应来治疗这种损伤至关重要。本综述将聚焦于神经保护的新技术,并描述既定治疗方法的最新进展。
尽管治疗性低温在治疗缺氧缺血性脑病中的首要地位已得到充分确立,但最近的研究表明,将体温降至33°C并持续72小时这一任意选定的方案可能确实是最合适的方法。产前镁治疗用于神经保护的最佳持续时间仍未确定,不过令人欣慰的是,即使镁治疗12小时或更短时间也能带来相当的神经学结局。与单独使用低温治疗相比,将褪黑素或促红细胞生成素等辅助疗法与治疗性低温相结合可带来良好的神经学结局。最后,基于干细胞的疗法在临床前研究中显示出相当大的潜力。
新生儿脑损伤的管理已取得重大进展。随着低温治疗最佳温度和持续时间的确立,使用辅助药物的联合疗法最具前景。基于干细胞的疗法和使用惰性气体等有前景的临床前方法需要通过临床试验加以证实。